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Myocardial infarctionWehave recently shown that the inhibition of histone deacetylases (HDAC) protects the heart against ischemia
and reperfusion (I/R) injury. The mechanism by which HDAC inhibition induces cardioprotection remains
unknown. We sought to investigate whether the genetic disruption of gp-91, a subunit of NADPH-oxidase,
wouldmitigate cardioprotection of HDAC inhibition.Wild-type and gp-91−/−micewere treatedwith a potent
inhibitor of HDACs, trichostatin A (TSA, 0.1 mg/kg, i.p.). Twenty-four hours later, the perfused hearts were
subjected to 30 min of ischemia and 30 min of reperfusion. HDAC inhibition in wild-type mice produced
marked improvements in ventricular functional recovery and the reduction of infarct size. TSA-induced
cardioprotection was eliminated with genetic deletion of gp91. Notably, Western blot and immunostaining
displayed a signiﬁcant increase in gp-91 inmyocardium following HDAC inhibition, which resulted in a mildly
subsequent increase in the production of reactive oxygen species (ROS). The pre-treatment of H9c2
cardiomyoblasts with TSA (50 nmol/l) decreased cell necrosis and increased viability in response to simulated
ischemia (SI), which was abrogated by the transfection of cells with gp-91 siRNA, but not by scrambled siRNA.
Furthermore, treatment of PLB-985 gp91+/+ cells with TSA increased the resistance to SI, which also
diminished with genetic disruption of gp91 in gp91phox-deﬁcient PLB-985 cells. TSA treatment inhibited the
increased active caspase-3 in H9c2 cardiomyoblasts and PLB-985 gp91+/+ cells exposed to SI, which were
prevented by knockdown of gp-91 by siRNA. These results suggest that a cascade consisting of gp-91 andHDAC
inhibition plays an essential role in orchestrating the cardioprotective effect.: +86 401 456 4812.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Histone acetyltransferases (HAT) and histone deacetylases (HDAC)
have recently garnered the attention because they have emerged as
an important mechanism in the regulation of a variety of cellular
responses. Histone acetylation is mediated by histone acetyltransfer-
ase, which results in the modiﬁcation of the structure of chromatin
leading to nucleosomal relaxation and altered transcriptional activa-
tion. In contrast, the reverse reaction is mediated by histone
deacetylase which induces deacetylation, chromatin condensation,
and transcriptional repression [1–5]. The acetylation status of the
histone tails is determined by the interplay between HATs and HDACs.
The opposing actions of HAT and HDACs allow gene expression to
be exquisitely regulated through chromatin remodeling.
Since the identiﬁcation of HDAC 1 (named HD 1) [6], over a dozen
of HDACs have been described in mammals [7]. These HDACs can be
categorized into three distinct classes. Class I HDACs consist of HDACs
1, 2, 3, and 8, which are ubiquitously expressed and predominantlylocated in nuclei. Class II HDACs includeHDACs 4, 5, 7 and 9. In contrast
to class I, class II HDACs exhibit a tissue speciﬁc pattern of expression.
HDAC 4 and HDAC 5 are found highly expressed in the heart, brain,
and skeletal muscle and shuttle between the nucleus and cytoplasm
[8–11]. We have recently demonstrated that the inhibition of histone
deacetylase with a selective inhibitor, trichostatin A, showed cardio-
protective effects against I/R injury [12]. This is consistent with the
observations that the inhibition of HDAC inmyocytes silences the fetal
gene activation, blocks cardiac hypertrophy and prevents cardiac
remodeling [13–15]. Furthermore, HDAC inhibition has previously
been shown to markedly decrease infarct size and reduce ischemia-
induced neurological deﬁcit scores in focal cerebral ischemia model of
rats [16].
ROS have a central role in diverse physiological and pathological
processes. When produced in large amounts by professional immune
cells such as neutrophil granulocytes, ROS have antimicrobial activity
serving in the ﬁrst line of host defense [17]. However, ROS produced at
low levels by non-immune cell have been implicated in growth factor
signaling, mitogenic response, apoptosis, and oxygen sensing [18,19].
Our study has suggested that a mild generation of ROS protected the
heart againstmyocardial necrosis [20]. A plethora of evidence has well
indicated that endothelial cells and vascular smooth muscle cells
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taining gp-91, a NADPH-oxidase subunit, which is amembrane-bound
component of NADPH-oxidase [21–23]. In addition to these mem-
brane-bound complexes, several other cytosolic proteins, including
p67, p47, p40 and rac, translocate to themembrane and associatewith
the gp-91 subunits and p22phox to assemble an enzyme complex that
facilitates electron transfer from NADPH to molecular oxygen, leading
to the generation of superoxides [24]. Even though the investigations
have supported that ROS generate a preconditioning effect to confer
protection, the role of gp-91 attributable to this event remains
unknown. Particularly, the inhibition of HDACs has been shown to
result in the generation of ROS in tumor cell lines [25]. The beneﬁcial
effects of mild ROS in preconditioned hearts were well addressed and
HDAC inhibition has been shown to effectively trigger a generation of
ROS. However, it also leaves the question open as to whether HDAC
inhibition co-ordinates with gp-91 to transduce a signaling pathway
to protect the heart against I/R injury. In this study, we investigated:
1) whether the cardioprotective effects induced with HDAC inhibitor,
TSA, could be diminished with the targeted deletion of gp-91;
2) whether HDAC inhibition would enhance gp-91 of NADPH-oxidase
and ROS production in myocardium; 3) whether genetic suppression
of gp-91 with siRNA would eliminate the resistance of H9c2 cardio-
myoblast cells in response to simulated ischemia in the presence of
HDAC inhibition; 4) whether the protective effects of HDAC inhibition
were absent in the gp91phox-deﬁcient PLB-985 cells but present in
wild-type cells; and 5) whether disruption of gp-91 would mitigate
the anti-apoptotic effect ofHDAC inhibition in the in vitro cultured cells
exposed to simulated ischemia. To the best of our knowledge, this is
the ﬁrst study to provide new insight into our understanding of novel
mechanisms of ischemic injury and developing therapeutic strategies
for heart disease.
2. Materials and methods
2.1. Animals
Adult male C57/BL6 wild-type and gp91−/− mice were supplied
by Jackson laboratories (Bar Harbor, Maine). All animal experiments
were conducted in accordancewith the guidelines on humane use and
care of laboratory animals for biomedical research published by the
National Institutes of Health. The experimental protocol was
approved and carried out in accordance with the guidelines adhered
to the Institutional Animal Care and Use Committee.
2.2. Chemical supplies and antibodies
Trichostatin A was obtained from Calbiochem (San Diego, CA).
N-(2-mercaptopropionyl)-gel electrophoresis supplies were obtained
fromBio-Rad Laboratories (Hercules, CA). Theperfusion chemicalswere
purchased fromSigma(St. Louis,MO).Gp-91polyclonal rabbit antibody,
β-actin, gp-91 siRNA and negative control scrambled siRNA were
purchased from Santa Cruz Biotechnology Inc. Mouse anti-sarcomeric
actinin antibody was obtained from Sigma (St. Louis, MO). Anti-rabbit
horseradish peroxidase-conjugated secondary antibody was purchased
from Amersham (Piscataway, NJ).
2.3. Langendorff isolated heart perfusion
The methodology of Langendorff's isolated perfused heart prepa-
ration has been described previously in detail [26–29]. Brieﬂy, mice
were anesthetized with an intraperitoneal injection (i.p.) of pento-
barbital sodium (120 mg/kg). The hearts were rapidly excised and
arrested in ice-cold Krebs–Henseleit buffer. They were then cannu-
lated via the ascending aorta for retrograde perfusion by the
Langendorff method using Krebs–Henseleit buffer containing (in
mM) 110 NaCl, 4.7 KCl, 1.2 MgSO4 7H2O, 2.5 CaCl2 2H2O, 11 glucose,1.2 KH2PO4, 25 NaHCO3, and 0.5 EDTA. The buffer, aerated with 95%
O2:5% CO2 to give a pH of 7.4 at 37 °C, was perfused at a constant
pressure of 55 mmHg. A water-ﬁlled latex balloon, attached to the tip
of polyethylene tubing, was then inﬂated sufﬁciently to provide a left
ventricular end-diastolic pressure (LVEDP) of 10 mmHg. Myocardial
function was measured including left ventricular developed pressure
(LVDP), LVEDP, RPP, heart rate and coronary ﬂow. LVDP was
calculated by subtracting LVEDP from the peak systolic pressure.
Rate pressure product (RPP), an index of cardiac work, was calculated
by multiplying LVDP with heart rate.
2.4. Measurement of myocardial infarction
The infarction size was measured with a modiﬁcation as
previously described [26–29]. At the end of reperfusion, hearts were
perfused with 10% triphenyltetrazolium chloride (TTC), and then
removed from the Langendorff perfusion apparatus. The frozen hearts
were then cut from apex to base into transverse slices. After staining,
10% TTC buffer was replaced, and then the slices were ﬁxed in
formaldehyde for measurement of the infarcted areas using computer
morphometry NIH image software (Image J 1. 36, NIH). The infarct
size was calculated and presented as the percentage of risk area,
deﬁned as the sum of total ventricular area minus cavities.
2.5. Experimental protocol 1
Mice were randomized into three experimental groups that
underwent the following treatments, as shown in Fig. 1: 1) Vehicle
group: wild-type mice receiving an i.p. injection of 0.1 ml vehicle
(DMSO); 2) TSA+wild-type group:wild-type animalswere treated the
sameasgroup1except that TSA (TSA, 0.1 mg/kg, i.p.)wasgiven towild-
type animals; 3) TSA+gp-91−/− group: the same as group 2 except
that mice with disruption of gp-91 were administered with TSA.
Twenty-four hours later, the hearts were subjected to 30 min of
stabilization and 30 min of ischemia followed by 30 min of reperfusion.
Another subset of animals without sustained ischemia and
reperfusion was treated with or without TSA solely for the purpose
of measuring the gp-91 protein. Animals were treated with TSA for
30 min, and heart tissues were collected. Cardiac lysates were
extracted as previously described [37]. Brieﬂy, the hearts were frozen
in liquid nitrogen, ground and suspended in 1 ml of lysis buffer con-
taining 50 mM Tris HCl (pH 7.4), 0.1 mM sodium orthovanadate,
50 mM sodium ﬂuoride, 150 mM sucrose, 1 mM phenylmethylsulfo-
nyl ﬂuoride (PMSF), 5 mM EDTA, 5 mM EGTA, 2 µg/ml leupeptin,
2 µg/ml aprotinin, and 5 µg/ml pepstatin A.Mixtures were homoge-
nized and microcentrifuged at 16,000×g for 20 min. The protein
content of the supernatant was determined using the detergent
compatible-protein assay (Bio-Rad). In addition, frozenhearts following
treatments were used for the detection of ROS in cardiac sections.
2.6. Western blot analysis
The proteins were detected using polycolonal anti-gp-91, active
caspase-3 from CalBiochem (San Diego, CA) and β-actin antibodies.
For immunoblotting, proteins (50 μg/lane)were separated by 6% SDS-
PAGE (gp-91) and 10% SDS-PAGE (active caspase-3). Proteins were
then transferred onto a nitrocellulose membrane for 2 h at 100V. The
membrane was blocked with 5% non-fat dry milk in 1× Tris-buffered
saline containing 0.5% Tween 20 for 1 h. The blotswere incubatedwith
respective primary antibodies (1:1000 dilution) for 2 h and visualized
by incubation with anti-rabbit horseradish peroxidase-conjugated
secondary antibody (1:5000 dilution) for 1 h. The immunoblots were
developed with the ECL Chemiluminescence Detection Reagent
(Amersham Pharmacia Biotech). The densitometric results were
normalized to the control group and expressed as percentages of
control values.
Fig. 1. Experimental protocols. See Materials and methods for the groups and treatments.
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H9c2 cardiomyoblast cells, a clonal line derived from rat heart
(ATCC, Rockville, MD), were grown in Dulbecco's modiﬁed Eagle's
medium (DMEM) with 10% fetal calf serum, 100 units/ml penicillin
and 0.1 mg/ml streptomycin. The siRNA transfections were done
according to the description in the manufacturer's protocol. The
negative control (scrambled) siRNA and gp-91 siRNA were mixed
with Lipofectamine™ 2000 (Invitrogen) at a ﬁnal concentration at
500 nmol/l of siRNA in medium, respectively. At 24 h of posttransfec-
tion, H9c2 cardiomyoblasts were subjected to simulated ischemia and
reperfusion, which have been well-established in our laboratory.
2.8. Simulated ischemia
For simulated ischemic stress in cultured cells, the protocol for
30 min of ischemia and 30 min of reperfusion was carried out
according to the experimental protocols 2 and 3. For TSA treatments,
H9c2 cardiomyoblasts and PLB-985 cells were cultured in a 5% CO2 at
37 °C and exposed to TSA (50 nmol/l) for 30 min before a subsequent
30 min of simulated ischemia was initiated. The SI medium was
consisted of (mM): NaCl 115, KCl 5, KH2PO4 1, MgSO4 1.2, CaCl2 2H2O
and HEPES 25 containing 5 mM potassium cyanide (KCN) and 20 mM
2-deoxy-D-glucose. Cyanide treatment was terminated by rinsing
twice with phosphate buffered saline (PBS). The medium was then
replaced by DMEM for 30 min to mimic reperfusion. In order to
elucidate the role of gp-91 in mediating TSA-induced cellularprotection, it would be important to utilize the cell line that lacks of
gp-91, which would provide us the genetic evidence to emphasize the
relationship of gp91 and HDAC inhibition in the regulation of cellular
response to stress stimulus. In this regard, we conducted another
separate experiment, in which gp91phox-deﬁcient PLB-985, PLB-985
wild-type cells were cultured as previously described [24,30]. The
execution of simulated ischemia and treatment of TSAwere performed
as described above. At the end of reperfusion, the cell viability and cell
necrosis were evaluated. Gp91phox-deﬁcient PLB-985 and PLB-985
wild-type cells were obtained from Dr. Dinauer, M, Department of
Pediatrics, Indiana University Medical Center, Indianapolis, Indiana.
2.9. Measurement of cell viability
The assessment of viabilities of H9c2 cardiomyocytes and PLB-985
cells was based upon the description and the principle of reduction of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) (St. Louis, MO) into blue formazan pigments in viable cells
[31]. At the end of the experiment, the medium was removed and the
cells washed with PBS. MTT (0.01 g/ml) were dissolved in PBS,
and 500 μl was added to each well. Cells were subsequently incubated
for 2 h at 37 °C. Cells were then washed twice with PBS and 1 ml of
HCl–isopropanol–Triton (1% HCl in isopropanol; 0.1% Triton X-100;
50:1) was added to each well for 5 min. The suspension was then
centrifuged at 16,000×g for 2 min. The optical densitywasdetermined
spectrophotometrically at a wavelength of 540 nm and the values
expressed as percentages of control values.
Fig. 2. Effect of TSA on post-ischemic ventricular function in wild-type and gp91−/−
mice. (A): left ventricular end-diastolic pressure (LVEDP); (B): rate pressure product
(RPP); (C): heart rate (HR) and (D): coronary efﬂuent (CF). TSA: trichostatin A; values
represent means±SE (n=4–6/group). *pb0.05.
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Loss of plasma membrane integrity (cell necrosis) was assessed
by measuring the activity of LDH in the supernatant. A 100 µl super-
natant was transferred into a 96-well plate. The release of lactate
dehydrogenase (LDH) in the culture medium from H9c2 cardiomyo-
blast cells and PLB-985 cells at the end of reperfusion was determined
as an indicator of cell necrosis using a commercially available kit
(Roche), as per the manufacturer's protocol with a modiﬁcation [32].
The optical density was determined spectrophotometrically at a
wavelength of 490 nm and the values expressed as percentages of
control values.
2.11. Detection of gp-91 and in situ production of superoxide inmyocardium
For immunoﬂuorescent staining, cardiac tissues were snap-frozen
in melting 2-methylbutane and the 10 μm-thick sections were cut
with a cryostat at −22 °C and mounted on plus charge slides (Fisher
Scientiﬁc). Sections were ﬁxed in 3.7% (vol/vol) paraformaldehyde
and then permeabilized in 0.5% Triton X-100 in PBS. The sectionswere
then incubated for 30 min in 0.5% goat serum/0.2% (vol/vol) Tween
20 and subsequently incubated with the following primary antibodies
for 1 h: a mouse monoclonal anti-sarcomeric actinin (1: 200 dilution)
for recognizing myocytes and rabbit polyclonal gp-91 for detecting
the gp-91. After three 5-minute washings in PBS, the following
secondary antibodies were applied: ﬂuorescein goat anti-rabbit IgG
(H+L) for rabbit polyclonal gp-91 and Texas red horse anti-mouse
IgG (H+L) for sarcomeric actinin. Nuclei were stained with 4′-6-
diamidino-2-phenylindole (DAPI) at a concentration of 10 μg/ml. In
situ detection of superoxide was performed as described previously
[33]. Brieﬂy, slides were placed into PBS for 30 min at room
temperature and then stained with dihydroethidium (DHE, 10 µM)
in PBS for 60 min in a moist chamber in the dark. The slides were
rinsed extensively with PBS and then coverslipped. Fluorescent
imaging was performed with a Nikon E2000 ﬂuorescence microscope,
equipped with MetaVue software for image analysis.
2.12. Statistics
All measurements are expressed as means±SE. Difference among
the groups was analyzed by one-way analysis of variance (ANOVA),
followed by post hoc Bonferroni correction or Student's unpaired t
test for two groups. Statistical differences were considered signiﬁcant
with a value of pb0.05.
3. Results
3.1. Myocardial functional recovery of HDAC inhibition depends on gp-91
Baseline ventricular function including LVSP, LVEDP, LVDP, rate
pressure product, and heart rate, were recorded among the groups.
There were no differences among the groups before ischemia. As
shown in Fig. 2, compared to the vehicle-treated animals, the
treatment of mice with TSA, resulted in a profound improvement in
post-ischemic left ventricular functional recovery in left ventricular
end-diastolic pressure. TSA-induced post-ischemic improvement in
LVEDP was abrogated in animals with disruption of the gp-91 subunit
of NADPH-oxidase (pb0.05, Fig. 2A). In addition, the recovery of the
RPP reached a marginal improvement following TSA treatment as
compared to vehicle-treated group (Fig. 2B). Similarly, disruption of
the gp-91 subunit of NADPH-oxidase abolished the recovery of rate
pressure product. Although TSA treatment in wild-type mice
demonstrated a mild increase in coronary efﬂuent, however, there
were no signiﬁcant differences in the heart rate and coronary ﬂow
among groups following ischemia and reperfusion (Fig. 2C and D).3.2. Disruption of gp-91 abolishes the infarct-sparing effect of HDAC
inhibition
Myocardial infarct size, an index of irreversible myocardial injury,
was measured. The infarct size in the vehicle group was 33.0±3%.
However, the infarct size in the TSA-treated groupwas reduced to 9.6±
2%, but the infarct-sparing effect following TSA treatmentwas increased
to 27±1% (pb0.001, Fig. 3). The data suggest that the reduction of
infarct size by HDAC inhibition is closely related with gp-91 subunit of
NADPH-oxidase subunit.
3.3. HDAC inhibition increases gp-91 and in situ ROS production
We examined the effect of TSA treatment on gp-91 content. As
shown in Fig. 4A, gp-91 was detectable in the myocardium from
control animals, and densitometric analysis demonstrates that TSA
treatment caused a remarkable increase in gp-91. There was no
signiﬁcant change in β actin, indicating that a gp-91 subunit of
NADPH-oxidase subunit was augmented following an increase of
hyperacetylation. In addition, as shown in Fig. 4C, immunoﬂuorescent
staining shows an increase in gp-91 signals following HDAC inhibition
as compared to the vehicle group. Furthermore, the detection of
superoxide with dihydroethidium staining indicates that TSA treat-
ment increased the production of superoxides (Fig. 5A–C).
3.4. HDAC inhibition increases the cell survival through gp-91
As shown in Fig. 6A, Western blot shows a reduction in expression
of gp-91 in H9c2 cardiomyoblast cells transfected with gp-91 siRNA
but not scrambled siRNA. This suggests that siRNA silencing effectively
knocked down gp-91 expression of H9c2 cadiomyoblasts. As shown in
Fig. 6B, simulated ischemic stimulus led to an increase of intracellular
LDH leakage as compared to the control, which signiﬁcantly decreased
Fig. 3. The effect of TSA on infarct size in wild-type and gp-91−/−mice (A) and representative infarct image from each group (B). At the end of experimental protocol as described in
Materials and methods, the hearts were stained with 2,3,5-triphenyltetrazolium chloride followed by ﬁxation in formalin. Viable areas are stained brick red, whereas infarcted are
gray or white. TSA: trichostatin A. Values represent means±SE (n=4–7). *pb0.001.
Fig. 4. (A): Representative Western blot showing the effect of TSA on gp-91 in the
myocardium. (B): Quantiﬁcation of gp-91 in the myocardium after TSA stimulation. The
densitometric signal was normalized to the vehicle group and expressed as a percentage.
Results are means±SE (n=3/group), *pb0.002 vs vehicle. (C): The myocytes were
stained with anti-sarcomeric actinin (red); gp-91 proteins were stained with anti-gp-91
(green). Nuclei were stained with 4′6-diamidino-2-phenylindole (DAPI, blue). Images
showanoverlay ofmyocytes, gp-91andnuclei. Left panel represents vehicle-treatedgroup
and right panel represents TSA-treated hearts. Bar=50 µm.
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genetic knockdown of gp-91 with siRNA remarkably prevented the
reduction of LDH leakage from HDAC inhibition, but the scrambled
siRNA did not exhibit effect of HDAC inhibition on LDH. Furthermore,
simulated ischemia decreased cell viability, which was profoundly
prevented by HDAC inhibition. The improvement in cell viability of
HDAC inhibition was also absent by the knockdown of gp-91 with
speciﬁc siRNA (Fig. 6C). To further conﬁrm the protective effect of gp-
91 on necrosis and viability, well-established gp-91 genetic mutant
cells were tested for their tolerance to ischemic stress. As shown in
Fig. 7A and B, simulated ischemic stimulus increased the necrosis and
decreased the cell viability of PLB-985 wild-type cells, but TSAFig. 5. Dihydroethidium (DHE) ﬂuorescence detection of ROS production in cardiac
sections. Cardiac sections fromvehicle-treated andTSA-treatedheartswere incubatedwith
10 µM of DHE. The DHE ﬂuorescence were visualized under microscopy. (A): Negative
control (without DHE incubation); (B): vehicle-treated hearts; (C): TSA-treated hearts.
Bar=50 µm.
Fig. 6. Western blot analysis of gp-91 in H9c2 cardiomyoblasts transfected with or
without gp-91 siRNA. (A): H9c2 cardiomyoblast were transfected with gp-91
(500 nmol/l) or scrambled siRNA (500 nmol/l) for 24 h to prepare protein lysates
and following immunoblotting assay. (B) The LDH release of H9c2 myocytes in culture
medium at the end of reperfusion (n=4/group). (C): Cell viability was measured using
the MTT cell viability assay (n=4/group). H9c2 cardiomyoblast cells were exposed to
simulated ischemia (KCN and 2-deoxy-D-glucose) and description of simulated
ischemia is provided under Materials and methods. HDAC inhibitor, trichostatin A
(50 nmol/l) was maintained in culture medium. Gp-91 and negative control siRNA
transfections are described as under Materials and methods. SI: Simulated ischemia.
LDH: Lactate dehydrogenase. Results are expressed as means±SE and the values
expressed as percentages of control values. *pb0.05.
Fig. 7. (A): The LDH release in culture medium at the end of reperfusion in PLB-985
wild-type and gp91phox-deﬁcient PLB-985 cells; (B): cell viability was measured using
the MTT cell viability assay. PLB-985 wild-type and gp91phox-deﬁcient PLB-985 cells
were exposed to simulated ischemia (KCN and 2-deoxy-D-glucose) and description of
simulated ischemia is provided under Materials and methods. HDAC inhibitor,
trichostatin A (50 nmol/l) was maintained in culture medium. LDH: lactate dehydro-
genase. Results are expressed as means±SE and the values expressed as percentages of
control values (n=4/group). SI: Simulated ischemia; Wt: wild-type PLB-895 cells;
Control: without simulated ischemia. *pb0.01.
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indicated by the increase in cell viability and reduction of LDH leakage.
These protective effects of TSA onwild-type PLB-985 cells were absent
in the gp91phox-deﬁcient PLB-985 cells. Thus, this data suggests that
gp-91 contributes to the HDAC inhibition-induced protection.
3.5. HDAC inhibition reduces apoptosis
We next examined whether HDAC inhibition through gp-91 affects
programmed cell death. We focused on assessing apoptosis by
measuring the appearance of active caspases, because apoptotic stimuli
activate the caspase cascade and the ﬁnal cleaved forms of effectorcaspases, such as caspase-3, then cleave substrates important in the
maintenance of cellular integrity.As shown in Fig. 8A andB, therewasan
active caspase-3 in H9c2 cardiomyoblasts exposed to simulated
ischemia stress. However, TSA treatment signiﬁcantly reduced the
content of active caspase-3,whichwasprevented bygenetic silencingof
gp-91, but not scrambled siRNA (pb0.05). Furthermore, as shown in
Fig. 8C andD, therewas an increase in active caspase-3 inbothwild-type
and gp91phox-deﬁcient PLB-985 cells exposed to simulated ischemia as
compared to the control group. However, TSA treatment decreased the
caspase-3 content in wild-type cells (pb0.05), but not in gp91phox-
deﬁcient PLB-985 cells. The caspase-3 contents in gp91phox-deﬁcient
PLB-985 cells were also higher than that of wild-type cells exposed to SI
in the presence of TSA. Collectively, the results indicate that gp-91 can
mediate the effects of HDAC inhibition through inhibiting a well-
characterized apoptotic pathway.
4. Discussion
4.1. Salient ﬁndings
The growing evidence indicates HDAC inhibition as a novel
signaling pathway to confer myocardial protection following I/R. The
Fig. 8. (A): Representative Western blots of caspase-3 in H9c2 cardiomyoblast cells
exposed to simulated ischemia; blots were probed with anti-active caspase-3; (B): the
densitometric signal was normalized to the control group and expressed as a
percentage. (C): Representative immunoblot showing active caspase-3 in PLB-985
wild-type and gp91phox-deﬁcient PLB-985 cells. (D): The densitometric signal was
normalized to the control group and expressed as a percentage. SI: Simulated ischemia;
Wt: wild-type PLB-985 cells; Control: without simulated ischemia. Results are
expressed as means±SE and the values expressed as percentages of control values
(n=3/group). *pb0.05.
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protective effect remains unknown. In this investigation, we have
demonstrated that the genetic deletion of gp91 abrogated myocardial
protection of HDAC inhibition. The inhibition of HDAC resulted in an
increase in gp-91 protein,whichwas associatedwith amild increase of
superoxide. Using interfering siRNA and well-established cell culture
models, we found that HDAC inhibition increased the resistance of
H9c2 cardiomyoblasts to simulated ischemia, which was indicated by
the reduction of cell necrosis and improvement in cell viability. The
beneﬁcial effects of HDAC inhibition on cell viability and necrosiswere
mitigated with genetic suppression of the gp-91 with siRNA.
Furthermore, stimulation of PLB-985 cells with TSA prevented the
cell necrosis and enhanced the cell viability, which were absent in the
gp91phox-deﬁcient PLB-985 cells that lack the gp-91. TSA also shows
the inhibition of cleaved caspase-3 protein, anti-apoptotic effect of
HDAC inhibitionwas blockedwith genetic knockdownof gp-91. Taken
together, this study is the ﬁrst demonstration to reveal that gp-91
subunit of NADPH-oxidase constitutes a novelmajor pathway of HDAC
inhibition to confer cardioprotection.
The class II HDACs are abundantly expressed in the heart [7,10].
TSA was originally isolated from Streptomyces hygroscopicus and acts
as a potent inhibitor of HDAC [34]. TSA binds to the deacetylase
catalytic core to form a tubular pocket, a zinc-binding site, and two
Asp–His charge-relay systems to inhibit the histone acetylase [35]. In
this study, we used TSA at 50 nmol/l to inhibit HDAC activity, which
produced the cardioprotective effect and a signiﬁcant increase in
acetylated histone 4 in hearts [12,13], suggesting the potency of
acetylation by HDAC inhibitor and providing a basis of TSA employed
in our study. The treatment of the heart with TSA caused an
improvement in ventricular functional recovery in post-ischemic
heart and the reduction of myocardial infarct size [12]. This is
consistent with previous observations in which either inhibition of
HDAC activity or knockdown of a speciﬁc HDAC reduces infarct size
and/or prevents cellular injury [36]. Furthermore, the protective
effects of HDAC inhibition have also been reported in hypertrophic
mice models, and cardiomyocytes [14,15,37]. Even though these
observations have characterized HDAC inhibition as a common
pathway to orchestrate myocardial protection, the mechanism by
which HDAC inhibitors confers cardioprotection is still poorly
understood. Interestingly, these beneﬁcial effects of HDAC inhibition
on the improvement of ventricular function and reduction of infarct
size in the wild-type were abrogated in mice with disruption of the
gp-91 subunit of NADPH-oxidase. These pieces of evidence suggest
that HDAC inhibition mediates the cardioprotection via gp-91 of
NADPH-oxidase. In addition, another observation indicates that mice
with an ablation of gp-91 show a slight lower systolic pressure, which
is attributable to vascular smoothmuscle tone [38]. However, we have
not demonstrated a signiﬁcant difference in cardiac function in
normal condition; it might be possible that gp-91 differently mediates
myocardial and vascular phenotypes. Some discrepancies may also be
related to the different models used.
Previous studies have well documented that the mild production
of ROS plays a pivotal role in initiating preconditioning effect which
protects the heart against ischemic injury [39–43]. The protective
effects of ROS in the preconditioned hearts are demonstrated to
involve the activation of the mitochondrial KATP channel and
transcriptional factor NF-κB, which constitute the most robust
signaling pathway against ischemia and reperfusion injury. In
addition, our previous works have already suggested that adminis-
tration of an inhibitor of nitric oxide markedly attenuated myocardial
protection by the activation of adenosine receptor A3 [27]. Consid-
erable observations indicate that the production of mild ROS is one of
the important mechanism(s) in development of cardioprotection,
whereas gp91phox subunit is centrally involved in the generation of
ROS in NADPH-oxidase. In addition to the fact that the gp91phox was
mostly conﬁned to vascular smooth muscles and endothelial cells
879T.C. Zhao et al. / Biochimica et Biophysica Acta 1803 (2010) 872–880[44], we have shown the presence of gp-91 in mouse myocardium,
providing a basis for us to investigate gp-91 in the ischemic heart [20].
The mechanism by which gp-91 was increased following HDAC
inhibition is not clear. It will be interesting to elucidate whether the
mediation of gp-91 with HDAC inhibition is associated with
transcriptional regulation or protein degradation.
Whether HDAC inhibition couples with gp-91 in the genesis of
cardioprotection, has never been tested. However, HDAC inhibitor,MS-
275 potently induced an increase in reactive oxygen species in U937
cells, followed by the loss of mitochondrial membrane potential [25].
This is consistent with the observation that HDAC inhibition mediated
cytotoxic effect via reactive oxidant species in nonproliferating chronic
lymphocytic leukemia. Despite the plethora of evidence showing a
potential link between the HDAC inhibition and production of ROS,
there was no study reporting a cascade consisting of HDAC inhibition
andgp-91 and their functional coupling. The loss of protective effects of
HDAC inhibition in gp-91−/− mice suggests the importance of this
workingmodule in the ischemic heart. H9c2 cardiomyoblast cells have
been widely used as a powerful in vitromodel to study I/R injury [45].
Using the in vitro H9c2 myocytes, we conducted the experiment of the
simulated ischemia, which is a well-established approach to study
cellular injury [31,45]. Treatment ofH9c2 cardiomyoblast cellswith the
HDAC inhibitor augmented the resistance to simulated ischemia by
enhancing cell viability and decreasing the cell necrosis. However,
these protective effects totally diminished in cells transfected with
interfering siRNA to knockdown the gp91 subunit. Furthermore, this
observationwas further conﬁrmed by the employed study inwhich the
enhanced resistance of wild-type cells to simulated ischemia by HDAC
inhibitionwas lost in gp91phox-deﬁcient PLB-985. In other observations
using different model and cell lines, HDAC inhibition has shown to be
pro-apoptosis and the sustained administration of angiotensin II
induced a gp-91 dependent hypertrophic heart failure [46]. The
reasons for these discrepancies are unclear, but it is likely to be related
to different responses in different models and the strength of gp-91
activation. In the present study, we do not investigate whether other
cytosolic subunits of NADPH-oxidases were also involved in HDAC
inhibition-induced cardioprotection. This is a subject matter which
merits further investigation.
In summary: In the present investigation, we have revealed a novel
mechanism by which the activation of gp-91, a subunit of NADPH-
oxidase following HDAC inhibition is essential to induce cardioprotec-
tion. HDAC inhibition caused an increase of gp-91 in the myocardium,
which led to a subsequent production of reactive oxidant species.
These data suggest a direct cause and effect relationship between
HDAC inhibition and gp-91 activation which orchestrates cardiopro-
tection. We have proven the central role of this novel pathway by
demonstrating the abrogation of cardioprotection by the targeted
deletion of gp-91 in mice. Furthermore, using in vitro H9c2
cardiomyoblast culture, siRNA gene silencing, as well as gp91phox-
deﬁcient cells, we show evidence that the reduction of cell necrosis
and increase in viability following HDAC inhibition were mitigated
with genetic knockdown or deletion of gp-91. Furthermore, HDAC
inhibition increased the anti-apoptotic effects in cultured cells
exposed to simulated ischemia. To the best of our knowledge, this is
the ﬁrst study providing direct evidence of mediating gp-91 by HDAC
inhibition to induce cardioprotective effects. Our investigation not
only provides new insight into our understanding of mechanisms of
myocardial I/R, but also suggests that therapeutic strategies targeting
this signaling pathway could be a novel and useful approach to the
protection of the ischemic myocardium.
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